# Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct03986073` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03986073](<https://clinicaltrials.gov/study/NCT03986073>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03986073

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT03986073. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-01 (actual); primary completion 2020-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT03986073, source copy `cardio:ctgov-nct03986073-2020-03-13`, retrieved 2026-10-26)
- Started: 2020-01-01 (actual) (ClinicalTrials.gov record NCT03986073, source copy `cardio:ctgov-nct03986073-2020-03-13`, retrieved 2026-10-26)
- Primary completion: 2020-06-30 (anticipated) (ClinicalTrials.gov record NCT03986073, source copy `cardio:ctgov-nct03986073-2020-03-13`, retrieved 2026-10-26)
- Completion: 2020-09-30 (anticipated) (ClinicalTrials.gov record NCT03986073, source copy `cardio:ctgov-nct03986073-2020-03-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03986073, source copy `cardio:ctgov-nct03986073-2020-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03986073-2020-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): TQ-F3083 capsule 10 mg
- Intervention (Drug): TQ-F3083 capsule 20 mg
- Intervention (Drug): TQ-F3083 blank analog capsule
- Intervention (Drug): TQ-F3083 blank analog capsule
- Intervention (Drug): Linagliptin blank analog tablet
- Intervention (Drug): Linagliptin tablet
- Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (`cardio:org-chia-tai-tianqing-pharmaceutical-group-co-ltd`)

## Provenance

Content hash: baa41b5110255bacc35a174ee62c72deae8ed80cd2e7851c78e49a6491be1c32
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
